Breaking News
Get 40% Off 0
🔎 See NVDA full ProTips for an instant risks or rewards Claim 40% OFF

Pro Research: Wall Street peers into CRISPR Therapeutics' future

Published Nov 27, 2023 17:52
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio

ProResearch offers comprehensive research analysis based on insights from top Wall Street analysts. These articles will soon be accessible exclusively to InvestingPro subscribers. Seize the opportunity to become a Pro user now, taking advantage of our exclusive Cyber Monday promotion offering up to a 55% discount.

CRISPR Therapeutics AG (NASDAQ:CRSP), a trailblazer in the biotechnology sector, has been drawing considerable attention from Wall Street, with its pioneering gene-based therapies. Recent analyses converge on the company's potential to revolutionize treatment for serious diseases, particularly with its CRISPR/Cas9 platform. As the company teeters on the brink of major regulatory approvals, investors are keenly observing the unfolding events, which could significantly alter the company's trajectory.

Company Overview

CRISPR Therapeutics has been making headlines with its gene-editing therapies, notably Exa-cel, aimed at treating Sickle Cell Disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The UK's recent approval of CASGEVY for SCD/TDT patients marks a significant milestone, not only for the company but also for the gene editing space at large. Analysts are optimistic, expecting the FDA's nod in the US by early December, with the potential to drive the company's stock upwards by 15-25%.

The biotech firm's in vivo programs, including CTX310 and CTX320 for cardiovascular diseases (CVD), are also under the spotlight. These therapies have demonstrated promising preclinical data, with CTX310 showing no off-target edits, and CTX320 achieving a durable reduction in Lp(a) levels. Clinical trials for these therapies are expected to commence in the first half of 2024, further expanding the company's innovative portfolio.

Financial Health and Stock Performance

CRISPR Therapeutics' financial health is robust, with a cash reserve of approximately $1.74 billion as of the third quarter of 2023. Despite downward revisions in EPS and revenue estimates for the year, the company's diverse pipeline and multiple partnerships offer significant growth prospects. The company's market capitalization has seen fluctuations, reflecting the dynamic nature of the biotech industry and investor sentiment.

Regulatory Landscape and Market Trends

The biotech industry is closely watching CRISPR Therapeutics as it approaches the PDUFA date for its SCD treatment. Analysts are cautiously optimistic about the commercial uptake, noting challenges related to severe patient restrictions and fertility loss concerns. The company's partner, Vertex Pharmaceuticals (NASDAQ:VRTX), sees 2024 as a foundational year for the launch, suggesting a gradual ramp-up in sales.

Competitive Landscape

The competitive landscape for CRISPR Therapeutics is multifaceted. On one hand, there is no immediate competition for CASGEVY in the UK. On the other hand, the company is navigating through a space where safety concerns and the risk of off-target editing are paramount. The potential approval of Exa-cel could significantly boost investor confidence and drive revenue for CRISPR Therapeutics, particularly as it is viewed as superior to competing therapies like Lovo-cel.

SWOT Analysis


  • Pioneering gene-editing therapies with potential for significant market disruption.
  • Robust cash reserves to support ongoing research and potential commercialization efforts.
  • Strong preclinical data for in vivo programs CTX310 and CTX320.


  • Potential regulatory challenges and safety concerns associated with gene therapies.
  • Dependence on the success of key therapies like Exa-cel for near-term valuation improvement.


  • Anticipation of FDA approval for Exa-cel, which could become the first gene editing medicine approved for SCD.
  • Expansion into clinical-stage in vivo editing with CTX310 and CTX320.


  • Uncertainty surrounding commercial uptake and infrastructure readiness for new therapies.
  • Risks associated with off-target effects and long-term safety of gene editing therapies.

Analysts Targets

  • BMO Capital Markets: Outperform rating with a price target of $98.00 (November 17, 2023).
  • RBC Capital Markets: Sector Perform rating with a price target of $50.00 (November 7, 2023).
  • Piper Sandler: Overweight rating with a price target of $105.00 (November 7, 2023).
  • JMP Securities: Market Outperform rating with a price target of $74.00 (November 7, 2023).
  • Barclays: Equal Weight rating with a price target of $56.00 (November 7, 2023).

The time span used for this analysis ranges from September to November 2023.

InvestingPro Insights

CRISPR Therapeutics AG (NASDAQ:CRSP) continues to show signs of a company on the move, as indicated by the real-time data and insights from InvestingPro. With a market capitalization of $5.42 billion and a significant revenue growth of 1106.49% in the last twelve months as of Q3 2023, the company's financial stature is noteworthy. Despite not being profitable during the same period, CRISPR Therapeutics' cash position is stronger than its debt, suggesting a solid balance sheet that could support its ambitious gene-editing projects.

InvestingPro Tips highlight that revenue growth has been accelerating for CRISPR Therapeutics, a key factor for investors expecting the company to capitalize on its innovative therapies. Moreover, with analysts revising their earnings upwards for the upcoming period, there appears to be a positive sentiment building around the company's future performance.

It's worth noting that the stock has experienced strong returns, with an 80.61% increase over the last month. This could be indicative of investor confidence in the company's near-term prospects, particularly as it approaches potential FDA approval for Exa-cel.

For investors looking to dive deeper into CRISPR Therapeutics' prospects, InvestingPro offers additional insights. Subscribers can access a total of 15 InvestingPro Tips for CRISPR Therapeutics, which provide a more comprehensive analysis of the company's financial health, market performance, and future outlook.

In light of Cyber Monday, InvestingPro subscriptions are now available at a special discount of up to 55%, allowing investors to take advantage of these valuable insights at an attractive price.

InvestingPro Data also sheds light on the company's valuation metrics, with a Price / Book ratio of 3.14 and a negative PEG ratio of -0.32 as of Q3 2023, suggesting that the stock may be trading at a high valuation relative to its growth prospects. This information could be crucial for investors trying to gauge the company's market position and make informed decisions.

As CRISPR Therapeutics continues its journey in the biotech industry, the InvestingPro platform remains a valuable resource for real-time data and expert analysis, helping investors keep a pulse on the company's evolving narrative.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Pro Research: Wall Street peers into CRISPR Therapeutics' future

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email